A new oral treatment for relapsing MS, called cladribine, will be made available on the NHS in England and Wales within the next three months.
Decision makers in Scotland and Northern Ireland are still considering whether to make cladribine available on the NHS.
Cladribine (also known as Mavenclad) is the thirteenth treatment to be approved by the National Institute for Health and Care Excellence (NICE) for relapsing MS. Unlike other oral treatments, which need to be taken every day, cladribine is taken as two courses of tablets, one year apart. Read on.